Evaluating protein cross-linking as a therapeutic strategy to stabilize SOD1 variants in a mouse model of familial ALS.
Mutations in the gene encoding Cu-Zn superoxide dismutase 1 (SOD1) cause a subset of familial amyotrophic lateral sclerosis (fALS) cases. A shared effect of these mutations is that SOD1, which is normally a stable dimer, dissociates into toxic monomers that seed toxic aggregates. Considerable resear...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-01-01
|
| Series: | PLoS Biology |
| Online Access: | https://journals.plos.org/plosbiology/article/file?id=10.1371/journal.pbio.3002462&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850062721837432832 |
|---|---|
| author | Md Amin Hossain Richa Sarin Daniel P Donnelly Brandon C Miller Alexandra Weiss Luke McAlary Svetlana V Antonyuk Joseph P Salisbury Jakal Amin Jeremy B Conway Samantha S Watson Jenifer N Winters Yu Xu Novera Alam Rutali R Brahme Haneyeh Shahbazian Durgalakshmi Sivasankar Swathi Padmakumar Aziza Sattarova Aparna C Ponmudiyan Tanvi Gawde David E Verrill Wensheng Yang Sunanda Kannapadi Leigh D Plant Jared R Auclair Lee Makowski Gregory A Petsko Dagmar Ringe Nathalie Y R Agar David J Greenblatt Mary Jo Ondrechen Yunqiu Chen Justin J Yerbury Roman Manetsch S Samar Hasnain Robert H Brown Jeffrey N Agar |
| author_facet | Md Amin Hossain Richa Sarin Daniel P Donnelly Brandon C Miller Alexandra Weiss Luke McAlary Svetlana V Antonyuk Joseph P Salisbury Jakal Amin Jeremy B Conway Samantha S Watson Jenifer N Winters Yu Xu Novera Alam Rutali R Brahme Haneyeh Shahbazian Durgalakshmi Sivasankar Swathi Padmakumar Aziza Sattarova Aparna C Ponmudiyan Tanvi Gawde David E Verrill Wensheng Yang Sunanda Kannapadi Leigh D Plant Jared R Auclair Lee Makowski Gregory A Petsko Dagmar Ringe Nathalie Y R Agar David J Greenblatt Mary Jo Ondrechen Yunqiu Chen Justin J Yerbury Roman Manetsch S Samar Hasnain Robert H Brown Jeffrey N Agar |
| author_sort | Md Amin Hossain |
| collection | DOAJ |
| description | Mutations in the gene encoding Cu-Zn superoxide dismutase 1 (SOD1) cause a subset of familial amyotrophic lateral sclerosis (fALS) cases. A shared effect of these mutations is that SOD1, which is normally a stable dimer, dissociates into toxic monomers that seed toxic aggregates. Considerable research effort has been devoted to developing compounds that stabilize the dimer of fALS SOD1 variants, but unfortunately, this has not yet resulted in a treatment. We hypothesized that cyclic thiosulfinate cross-linkers, which selectively target a rare, 2 cysteine-containing motif, can stabilize fALS-causing SOD1 variants in vivo. We created a library of chemically diverse cyclic thiosulfinates and determined structure-cross-linking-activity relationships. A pre-lead compound, "S-XL6," was selected based upon its cross-linking rate and drug-like properties. Co-crystallographic structure clearly establishes the binding of S-XL6 at Cys 111 bridging the monomers and stabilizing the SOD1 dimer. Biophysical studies reveal that the degree of stabilization afforded by S-XL6 (up to 24°C) is unprecedented for fALS, and to our knowledge, for any protein target of any kinetic stabilizer. Gene silencing and protein degrading therapeutic approaches require careful dose titration to balance the benefit of diminished fALS SOD1 expression with the toxic loss-of-enzymatic function. We show that S-XL6 does not share this liability because it rescues the activity of fALS SOD1 variants. No pharmacological agent has been proven to bind to SOD1 in vivo. Here, using a fALS mouse model, we demonstrate oral bioavailability; rapid engagement of SOD1G93A by S-XL6 that increases SOD1G93A's in vivo half-life; and that S-XL6 crosses the blood-brain barrier. S-XL6 demonstrated a degree of selectivity by avoiding off-target binding to plasma proteins. Taken together, our results indicate that cyclic thiosulfinate-mediated SOD1 stabilization should receive further attention as a potential therapeutic approach for fALS. |
| format | Article |
| id | doaj-art-ae0b075acaa84b09a950667731983ac1 |
| institution | DOAJ |
| issn | 1544-9173 1545-7885 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Biology |
| spelling | doaj-art-ae0b075acaa84b09a950667731983ac12025-08-20T02:49:50ZengPublic Library of Science (PLoS)PLoS Biology1544-91731545-78852024-01-01221e300246210.1371/journal.pbio.3002462Evaluating protein cross-linking as a therapeutic strategy to stabilize SOD1 variants in a mouse model of familial ALS.Md Amin HossainRicha SarinDaniel P DonnellyBrandon C MillerAlexandra WeissLuke McAlarySvetlana V AntonyukJoseph P SalisburyJakal AminJeremy B ConwaySamantha S WatsonJenifer N WintersYu XuNovera AlamRutali R BrahmeHaneyeh ShahbazianDurgalakshmi SivasankarSwathi PadmakumarAziza SattarovaAparna C PonmudiyanTanvi GawdeDavid E VerrillWensheng YangSunanda KannapadiLeigh D PlantJared R AuclairLee MakowskiGregory A PetskoDagmar RingeNathalie Y R AgarDavid J GreenblattMary Jo OndrechenYunqiu ChenJustin J YerburyRoman ManetschS Samar HasnainRobert H BrownJeffrey N AgarMutations in the gene encoding Cu-Zn superoxide dismutase 1 (SOD1) cause a subset of familial amyotrophic lateral sclerosis (fALS) cases. A shared effect of these mutations is that SOD1, which is normally a stable dimer, dissociates into toxic monomers that seed toxic aggregates. Considerable research effort has been devoted to developing compounds that stabilize the dimer of fALS SOD1 variants, but unfortunately, this has not yet resulted in a treatment. We hypothesized that cyclic thiosulfinate cross-linkers, which selectively target a rare, 2 cysteine-containing motif, can stabilize fALS-causing SOD1 variants in vivo. We created a library of chemically diverse cyclic thiosulfinates and determined structure-cross-linking-activity relationships. A pre-lead compound, "S-XL6," was selected based upon its cross-linking rate and drug-like properties. Co-crystallographic structure clearly establishes the binding of S-XL6 at Cys 111 bridging the monomers and stabilizing the SOD1 dimer. Biophysical studies reveal that the degree of stabilization afforded by S-XL6 (up to 24°C) is unprecedented for fALS, and to our knowledge, for any protein target of any kinetic stabilizer. Gene silencing and protein degrading therapeutic approaches require careful dose titration to balance the benefit of diminished fALS SOD1 expression with the toxic loss-of-enzymatic function. We show that S-XL6 does not share this liability because it rescues the activity of fALS SOD1 variants. No pharmacological agent has been proven to bind to SOD1 in vivo. Here, using a fALS mouse model, we demonstrate oral bioavailability; rapid engagement of SOD1G93A by S-XL6 that increases SOD1G93A's in vivo half-life; and that S-XL6 crosses the blood-brain barrier. S-XL6 demonstrated a degree of selectivity by avoiding off-target binding to plasma proteins. Taken together, our results indicate that cyclic thiosulfinate-mediated SOD1 stabilization should receive further attention as a potential therapeutic approach for fALS.https://journals.plos.org/plosbiology/article/file?id=10.1371/journal.pbio.3002462&type=printable |
| spellingShingle | Md Amin Hossain Richa Sarin Daniel P Donnelly Brandon C Miller Alexandra Weiss Luke McAlary Svetlana V Antonyuk Joseph P Salisbury Jakal Amin Jeremy B Conway Samantha S Watson Jenifer N Winters Yu Xu Novera Alam Rutali R Brahme Haneyeh Shahbazian Durgalakshmi Sivasankar Swathi Padmakumar Aziza Sattarova Aparna C Ponmudiyan Tanvi Gawde David E Verrill Wensheng Yang Sunanda Kannapadi Leigh D Plant Jared R Auclair Lee Makowski Gregory A Petsko Dagmar Ringe Nathalie Y R Agar David J Greenblatt Mary Jo Ondrechen Yunqiu Chen Justin J Yerbury Roman Manetsch S Samar Hasnain Robert H Brown Jeffrey N Agar Evaluating protein cross-linking as a therapeutic strategy to stabilize SOD1 variants in a mouse model of familial ALS. PLoS Biology |
| title | Evaluating protein cross-linking as a therapeutic strategy to stabilize SOD1 variants in a mouse model of familial ALS. |
| title_full | Evaluating protein cross-linking as a therapeutic strategy to stabilize SOD1 variants in a mouse model of familial ALS. |
| title_fullStr | Evaluating protein cross-linking as a therapeutic strategy to stabilize SOD1 variants in a mouse model of familial ALS. |
| title_full_unstemmed | Evaluating protein cross-linking as a therapeutic strategy to stabilize SOD1 variants in a mouse model of familial ALS. |
| title_short | Evaluating protein cross-linking as a therapeutic strategy to stabilize SOD1 variants in a mouse model of familial ALS. |
| title_sort | evaluating protein cross linking as a therapeutic strategy to stabilize sod1 variants in a mouse model of familial als |
| url | https://journals.plos.org/plosbiology/article/file?id=10.1371/journal.pbio.3002462&type=printable |
| work_keys_str_mv | AT mdaminhossain evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT richasarin evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT danielpdonnelly evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT brandoncmiller evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT alexandraweiss evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT lukemcalary evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT svetlanavantonyuk evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT josephpsalisbury evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT jakalamin evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT jeremybconway evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT samanthaswatson evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT jenifernwinters evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT yuxu evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT noveraalam evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT rutalirbrahme evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT haneyehshahbazian evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT durgalakshmisivasankar evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT swathipadmakumar evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT azizasattarova evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT aparnacponmudiyan evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT tanvigawde evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT davideverrill evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT wenshengyang evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT sunandakannapadi evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT leighdplant evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT jaredrauclair evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT leemakowski evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT gregoryapetsko evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT dagmarringe evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT nathalieyragar evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT davidjgreenblatt evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT maryjoondrechen evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT yunqiuchen evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT justinjyerbury evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT romanmanetsch evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT ssamarhasnain evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT roberthbrown evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals AT jeffreynagar evaluatingproteincrosslinkingasatherapeuticstrategytostabilizesod1variantsinamousemodeloffamilialals |